Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04317781
Recruitment Status : Recruiting
First Posted : March 23, 2020
Last Update Posted : May 29, 2020
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This phase II trial studies the side effects of tagraxofusp in treating patients with blastic plasmacytoid dendritic cell neoplasm after stem cell transplant. Tagraxofusp is a type of immunotoxin that is made by linking a protein called IL-3 to a toxic substance. Tagraxofusp may help find cancer cells that express IL-3 and kill them without harming normal cells.

Condition or disease Intervention/treatment Phase
Blastic Plasmacytoid Dendritic Cell Neoplasm Biological: Tagraxofusp-erzs Phase 2

Detailed Description:

PRIMARY OBJECTIVE:

I. To evaluate the safety of tagraxofusp-erzs (tagraxofusp) in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) after autologous (auto) or allogeneic (allo) hematopoietic cell transplantation (HCT).

SECONDARY OBJECTIVES:

I. To estimate progression-free survival (PFS) in patients with BPDCN receiving maintenance therapy with tagraxofusp after auto-HCT or allo-HCT.

II. To estimate the overall survival (OS) in patients with BPDCN receiving maintenance therapy with tagraxofusp after auto-HCT or allo-HCT.

OUTLINE:

Within day 45 and 120 after stem cell transplant, patients receive tagraxofusp-erzs intravenously (IV) over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for up to 1 year.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Tagraxofusp (SL-401) Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation
Actual Study Start Date : March 27, 2020
Estimated Primary Completion Date : August 31, 2021
Estimated Study Completion Date : August 31, 2021


Arm Intervention/treatment
Experimental: Treatment (tagraxofusp-erzs)
Within day 45 and 120 after stem cell transplant, patients receive tagraxofusp-erzs IV over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Biological: Tagraxofusp-erzs
Given IV
Other Names:
  • Diphtheria Toxin(388)-Interleukin-3 Fusion Protein
  • DT(388)-IL3 Fusion Protein
  • DT388IL3 fusion protein
  • Elzonris
  • IL3R-targeting Fusion Protein SL-401
  • SL-401
  • TAGRAXOFUSP
  • Tagraxofusp ERZS




Primary Outcome Measures :
  1. Tolerability of tagraxofusp post-stem cell transplantation (SCT) [ Time Frame: Up to 1 year ]
    Tolerability is defined as receipt of at least 75% of planned tagraxofusp doses in at least 4 cycles of therapy. The percentage of patients considered 'tolerating' will be presented along with the associated 95% exact confidence interval.


Secondary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: From treatment start date to date of disease progression or death, assessed up to 1 year ]
    Will be estimated using the Kaplan-Meier method. Median PFS as well as rates with corresponding 95% confidence intervals will be presented.

  2. Overall survival (OS) [ Time Frame: From treatment start date to death, assessed up to 1 year ]
    Will be estimated using the Kaplan-Meier method. Median OS as well as rates with corresponding 95% confidence intervals will be presented.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eligible patients will be aged >= 18 years. Pediatric patients age 2 years and older will be considered on a case by case basis.
  • Diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) according to World Health Organization (WHO) classification or confirmed by hematopathology
  • The patients must be in partial response or better
  • > 30 days post-transplant without active or chronic infections
  • Karnofsky performance status >= 60%; Lansky >= 60
  • Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal by multigated acquisition (MUGA) scan or echocardiogram within 30 days of first protocol treatment
  • Diffusion capacity of the lung for carbon monoxide (DLCO) > 40% of predicted value (corrected for hemoglobin) within 3 months of registration
  • Forced expiratory volume in 1 second (FEV1) > 40% of predicted value within 3 months of registration
  • Forced vital capacity (FVC) > 40% of predicted value within 3 months of registration
  • Serum creatinine =< 1.5 mg/dL (133 mmol/L)
  • Serum albumin >= 3.2 g/dL (or >= 32 g/L) without IV albumin within the previous 72 hours
  • Bilirubin =< 1.5 x the upper limit of normal ([ULN] except patients with Gilbert syndrome in whom bilirubin level of > 1.5 x ULN will be allowed)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
  • Hemoglobin >= 8 g/dL with or without transfusion in the last 7 days
  • Absolute neutrophil count (ANC) >= 1000 without granulocyte colony stimulating factor (GCSF) or granulocyte-macrophage colony-stimulating factor (GMCSF) in the last 2 weeks prior to screening
  • Platelets >= 50,000micro/mL
  • For allo-HCT, no >= grade 2 visceral (gut or liver) acute graft versus host disease (GVHD) and no >= grade 3 or any other acute GVHD (patients with chronic GVHD will be allowed at the discretion of the investigator)
  • Patient agrees to use acceptable contraceptive methods for the duration of time in the study, and to continue to use acceptable contraceptive methods for 2 months after the last tagraxofusp infusion
  • Woman of child bearing potential (WOCBP) with a negative serum or urine pregnancy test within 14 days of tagraxofusp treatment
  • Patient or patient's legal representative, parent(s) or guardian able to sign informed consent
  • The patient can adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment

Exclusion Criteria:

  • The patient has persistent clinically significant non-hematologic toxicities >= grade 2 (excluding alopecia, nausea, and fatigue)
  • Evidence of central nervous system (CNS) involvement
  • Uncontrolled and active pulmonary disease
  • Requirement for oxygen treatment
  • Receiving chemotherapy, radiotherapy or other anti-cancer therapy within 14 days of first dose of study drug. There must be at least a 6-week interval from the last immunotherapy therapy
  • Uncontrolled infection
  • Human immunodeficiency virus (HIV)/hepatitis B and/or C
  • Any history of invasive malignancy in the last 2 years excluding any malignancy such as cervical cancer or skin cancer (excluding melanoma) that is considered cured at the time of screening
  • Pregnant or breast-feeding woman
  • Patient has uncontrolled intercurrent illness or medical/psychiatric condition that would limit compliance with study requirements or that would in the investigator's opinion place the patient at an unacceptably high risk for toxicities
  • Clinical significant cardiopulmonary disease including uncontrolled or New York Heart Association (NYHA) class 3 or 4 congestive heart failure, uncontrolled angina, uncontrolled hypertension, uncontrolled arrhythmia, myocardial infarction or stroke within 6 months of first protocol treatment or corrected QT (QTc) > 480 ms

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04317781


Contacts
Layout table for location contacts
Contact: Qaiser Bashir 713-792-8750 qbashir@mdanderson.org

Locations
Layout table for location information
United States, Texas
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Qaiser Bashir    713-792-8750      
Principal Investigator: Qaiser Bashir         
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Qaiser Bashir M.D. Anderson Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT04317781    
Other Study ID Numbers: 2018-0646
NCI-2019-03832 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2018-0646 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
First Posted: March 23, 2020    Key Record Dates
Last Update Posted: May 29, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms